Abstract
The cyclic-AMP response element-binding protein (CREB) is a nuclear transcription factor activated by phosphorylation at Ser133 by multiple serine/threonine (Ser/Thr) kinases. Upon phosphorylation, CREB binds the transcriptional co-activator, CBP (CREB-binding protein), to initiate CREB-dependent gene transcription. CREB is a critical regulator of cell differentiation, proliferation and survival in the nervous system. Recent studies have shown that CREB is involved tumor initiation, progression and metastasis, supporting its role as a proto-oncogene. Overexpression and overactivation of CREB were observed in cancer tissues from patients with prostate cancer, breast cancer, non-small-cell lung cancer and acute leukemia while down-regulation of CREB in several distinct cancer cell lines resulted in inhibition of cell proliferation and induction of apoptosis, suggesting that CREB may be a promising target for cancer therapy. Although CREB, as a transcription factor, is a challenging target for small molecules, various small molecules have been discovered to inhibit CREB phosphorylation, CREB-DNA, or CREB-CBP interaction. These results suggest that CREB is a suitable transcription factor for drug targeting and therefore targeting CREB could represent a novel strategy for cancer therapy.
Keywords: Cancer, CBP, CREB, inhibitors, KID, KIX, naphthol AS-E, Ro 31-8220
Current Cancer Drug Targets
Title: Targeting CREB for Cancer Therapy: Friend or Foe
Volume: 10 Issue: 4
Author(s): X. Xiao, B.X. Li, B. Mitton, A. Ikeda and K.M. Sakamoto
Affiliation:
Keywords: Cancer, CBP, CREB, inhibitors, KID, KIX, naphthol AS-E, Ro 31-8220
Abstract: The cyclic-AMP response element-binding protein (CREB) is a nuclear transcription factor activated by phosphorylation at Ser133 by multiple serine/threonine (Ser/Thr) kinases. Upon phosphorylation, CREB binds the transcriptional co-activator, CBP (CREB-binding protein), to initiate CREB-dependent gene transcription. CREB is a critical regulator of cell differentiation, proliferation and survival in the nervous system. Recent studies have shown that CREB is involved tumor initiation, progression and metastasis, supporting its role as a proto-oncogene. Overexpression and overactivation of CREB were observed in cancer tissues from patients with prostate cancer, breast cancer, non-small-cell lung cancer and acute leukemia while down-regulation of CREB in several distinct cancer cell lines resulted in inhibition of cell proliferation and induction of apoptosis, suggesting that CREB may be a promising target for cancer therapy. Although CREB, as a transcription factor, is a challenging target for small molecules, various small molecules have been discovered to inhibit CREB phosphorylation, CREB-DNA, or CREB-CBP interaction. These results suggest that CREB is a suitable transcription factor for drug targeting and therefore targeting CREB could represent a novel strategy for cancer therapy.
Export Options
About this article
Cite this article as:
Xiao X., Li B.X., Mitton B., Ikeda A. and Sakamoto K.M., Targeting CREB for Cancer Therapy: Friend or Foe, Current Cancer Drug Targets 2010; 10 (4) . https://dx.doi.org/10.2174/156800910791208535
DOI https://dx.doi.org/10.2174/156800910791208535 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cognitive Functions under Anti-HER2 Targeted Therapy in Cancer Patients: A Scoping Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Genomics Can Advance The Potential For Probiotic Cultures To Improve Liver And Overall Health
Current Pharmaceutical Design Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets Triple-negative Breast Cancer and Poly(ADP-ribose) Polymerase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Retinal Ganglion Cell Gene Therapy and Visual System Repair
Current Gene Therapy Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Editorial (Thematic Issue: Elderly Cancer Patients in the 3rd Millenium: Between Hope and Reality. Introduction)
Anti-Cancer Agents in Medicinal Chemistry Suppression of HIV-1 Viral Replication by Inhibiting Drug Efflux Transporters in Activated Macrophages
Current HIV Research Design of Novel Antitumor DNA Alkylating Agents: The Benzacronycine Series
Current Medicinal Chemistry - Anti-Cancer Agents Modulatory Effects of Peroxisome Proliferator-Activated Receptor-γ on CXCR3 Chemokines
Recent Patents on Inflammation & Allergy Drug Discovery Vitamin D and the Adaptive Immune System with Special Emphasis to Allergic Reactions and Allograft Rejection
Inflammation & Allergy - Drug Targets (Discontinued) MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Exploring Photoactivated Disinfection-Induced Bystander Effects on Microbial Biofilms of Aggregatibacter actinomycetemcomitans
Infectious Disorders - Drug Targets γ-Secretase Substrates and their Implications for Drug Development in Alzheimer's Disease
Current Topics in Medicinal Chemistry Unveiling Role of MicroRNAs as Treatment Strategy and Prognostic Markers in Triple Negative Breast Cancer
Current Pharmaceutical Biotechnology Ligand-Based Pharmacophore Modeling, Atom-Based 3D-QSAR and Molecular Docking Studies on Substituted Thiazoles and Thiophenes as Polo-Like Kinase 1 (Plk1) Inhibitors
Combinatorial Chemistry & High Throughput Screening Consumption of Cooked Navy Bean Powders Modulate the Canine Fecal and Urine Metabolome
Current Metabolomics Polymeric Drug Delivery Approaches for Colon Targeting: A Review
Drug Delivery Letters Phosphodiesterase Inhibitors as Therapeutics for Traumatic Brain Injury
Current Pharmaceutical Design